Chemotherapy-free anlotinib-based regimens in advanced non-small cell lung cancer: a real-world retrospective cohort study
Authors:
- Yuqing ZhangYZYuqing Zhang
- Yumeng HanYHYumeng Han
- Kaiyuan HuiKHKaiyuan Hui
- Xiaodong JiangXJXiaodong Jiang
Open Access
- 1 April 2026
- journal article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (4) , 346
Abstract
Background: Anlotinib is established as a standard later-line treatment for advanced non-small cell lung cancer (NSCLC). However, the real-world efficacy of anlotinib-based chemotherapy-free combinations—particularly in earlier lines of therapy—remains insufficiently characterized. This study aimed to evaluate the survival outcomes of anlotinib monotherapy versus combination regimens and assess the impact of treatment line on efficacy. Methods: In this retrospective, real-world observational study, we analyzed 170 patients with advanced NSCLC. Patients were stratified into three cohorts: anlotinib monotherapy (Group A, n=62), anlotinib plus immunotherapy (Group A+I, n=57), and anlotinib plus targeted therapy (Group A+T, n=51). The primary endpoints were progression-free survival (PFS) and overall survival (OS), analyzed using Kaplan-Meier methods and Cox proportional hazards models. Results: The median PFS and OS for the entire cohort were 10 and 18.5 months, respectively. The objective response rate (ORR) and disease control rate (DCR) for the entire population were 17.6% and 84.8%, respectively. In the subgroups, the ORR was 18.8% (A+I) and 23.1% (A+T) vs. 10.5% (monotherapy), while the DCR was 93.8% (A+I) and 82.1% (A+T) vs. 76.3% (monotherapy). Compared with monotherapy, combination regimens demonstrated superior survival benefits. Specifically, the A+I group showed significantly reduced risks of progression [hazard ratio (HR): 0.461, P=0.001] and mortality (HR: 0.576, P=0.03). Similarly, the A+T group exhibited marked improvements in PFS (median 13.5 vs. 4.0 months; HR: 0.360, Pvs. 10.0 months; HR: 0.332, Pvs. 8.5 months) and OS (37.0 vs. 14.0 months) compared to third-line use. Notably, among patients with driver mutations, the A+T regimen extended median OS to 26.5 months compared to 10.0 months in the monotherapy group. Lack of prior anti-angiogenic therapy was identified as an independent predictor for improved PFS. Conclusions: Anlotinib-based, chemotherapy-free regimens demonstrate significantly greater efficacy than anlotinib monotherapy in advanced NSCLC. Furthermore, the upstream application of these regimens in earlier treatment lines is associated with markedly prolonged survival. These findings support anlotinib-based combinations as a promising chemotherapy-sparing strategy, particularly for patients unsuitable for or refusing chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2022
- Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing TrialsInternational Journal of Molecular Sciences, 2022
- First-Line Immunotherapy for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2022
- Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in NeuroblastomaClinical Cancer Research, 2021
- Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLCJournal of Thoracic Oncology, 2021
- Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialThe Lancet, 2021
- Anlotinib as a molecular targeted therapy for tumors (Review)Oncology Letters, 2020
- The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trialTranslational Lung Cancer Research, 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2019
- Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapyEuropean Respiratory Journal, 2018